Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor By Investing.com
Ipsen secures ex-U.S. regulatory and industrial rights to tovorafenib for commonest childhood mind tumor, pediatric low-grade glioma (pLGG), and any ...
